Electra Therapeutics (NASDAQ:ETRA) Raised to Hold at Zacks Research

Electra Therapeutics (NASDAQ:ETRA) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

Several other equities research analysts have also recently commented on the company. Cantor Fitzgerald began coverage on Electra Therapeutics in a research report on Tuesday. They set an “overweight” rating on the stock. TD Cowen started coverage on Electra Therapeutics in a report on Tuesday. They issued a “buy” rating for the company. Wall Street Zen raised Electra Therapeutics to a “hold” rating in a research report on Saturday, September 26th. Jefferies Financial Group started coverage on Electra Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $32.00 target price for the company. Finally, Evercore started coverage on shares of Electra Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $36.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Electra Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $34.00.

Electra Therapeutics Stock Down 2.1%

Electra Therapeutics stock opened at $8.75 on Wednesday. Electra Therapeutics has a 12 month low of $8.50 and a 12 month high of $15.50.

Insider Buying and Selling at Electra Therapeutics

In other Electra Therapeutics news, Director Orbimed Advisors Llc purchased 1,333,333 shares of the company’s stock in a transaction dated Monday, September 21st. The shares were acquired at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the purchase, the director directly owned 5,126,891 shares of the company’s stock, valued at $76,903,365. The trade was a 35.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Carl Gordon acquired 1,333,333 shares of the business’s stock in a transaction dated Monday, September 21st. The shares were acquired at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the transaction, the director owned 5,126,891 shares in the company, valued at approximately $76,903,365. This trade represents a 35.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

About Electra Therapeutics

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.